Top Tech Companies (144)
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
MultiplAI Health is a preventive medicine company pioneering blood screening for cardiovascular and other complex diseases. Powered by genomic RNAseq, proprietary data transformation, and comprehensive AI analysis, our test transforms a single blood sample into a precision, actionable risk assessment to drive proactive health management that will extend lifespan. We have a laboratory-validated prototype and are conducting our sixth clinical...
Phytoform are making agriculture sustainable & unlocking the genetic potential of plants.
Built for precision, designed for patients. Sania [sah-nee-ah] is a London based biotech company building therapeutics that transform the lives of people with diseases of dysfunctional neural circuits.
GlamorousAI is bringing drugs to every target though its AI-first SaaS platform for drug discovery, RosalindAI. RosalindAI advancing AI to address small, noisy and sparse data challenges with a technology validated experimentally in the lab.
Entia is an oncology service provider supporting more effective cancer care by predicting and preventing treatment side effects. Our unique remote patient monitoring solutions, including the world's first at-home full blood count analyser, identify patients at risk of complications early on and enable timely interventions that can result in more time on treatment, fewer unplanned hospitalisations and the potential deliver...
Wellcome supports science to solve the urgent health challenges facing everyone. We’re a global charitable foundation. And we want everyone to benefit from science’s potential to improve health and save lives. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, climate and health and infectious diseases. Ask us questions, comment on posts...
BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we...
Winner of the 2022 Prix Galien UK Award for "Best Digital Health Solution". The equivalent of the Nobel Prize within Life Science. At behold.ai we utilise cutting-edge science to pioneer new forms of diagnostic medicine; this revolutionary approach to healthcare is a step change in the treatment and prevention of diseases, benefiting patients on a global scale
We use cutting-edge gene editing techniques to develop healthier, hardier and more sustainable crop varieties that flourish even in the face of climate change so local growing communities can thrive, and we can sustain the world’s food supply
Amber Therapeutics is a University of Oxford spinout developing next-generation, intelligent bioelectrical therapies to transform clinical outcomes in patients with functional disorders of the peripheral nervous system. Amber’s approach leverages closed-loop intelligence to create ‘synthetic reflex arcs’ that can sense, interpret, adapt and respond to a patient’s individual signals thereby restoring normal physiological function. Amber Therapeutics was founded by a...
At Epoch, we use advanced biodesign to develop natural solutions to unnatural problems. We have started by designing and scaling the first enzymes capable of transforming plastics into low-carbon, circular chemicals.
Valink Therapeutics (formerly LiliumX) is a spinout of the University of Oxford, focused on the development of next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating bi-/multispecificity, multivalency and drug-conjugation into a single discovery process via our Universal Assembly Platform™. Our internal research focus is on solid tumours poorly addressed by immunotherapy, in addition...
CHAIN Biotechnology was founded in 2014, by serial entrepreneur Dr Edward Green, to exploit the therapeutic potential of Clostridia bacteria found in the human gut microbiome. CHAIN has built an impressive technical team of molecular biology, microbiology, microbiome and fermentation specialists focused on the biotechnology development of Clostridia. In addition, CHAIN leverages synthetic biology expertise from the Synthetic Biology Research...
Clustermarket is the world-leading lab management system helping laboratories optimize their operations and accelerate results. Clustermarket equips research teams with an easy-to-use software solution enabling them to coordinate equipment usage, plan maintenance activities, and generate reports and forecasts for resource planning. The intuitive system is designed for fast implementation and high adoption within the organization, whilst also offering integrations with...
More sustainable products, for everyday use Carbon chains are the backbones in most modern products, extracted from crude oil and converted into anything from materials to ingredients. Scindo is working towards a circular future, where your favourite products are sustainably manufactured from renewable or recycled feedstocks. We are developing cutting-edge enzyme systems to address two global challenges: the reliance on...
Tailor Bio is developing an AI-driven drug discovery platform for pan-cancer precision medicine. We're doing this by focussing on Chromosomal Instability, a genomic phenomenon present in 80% of all cancers.
Pear Bio is a computational biology company that uses organ-on-a-chip and computer vision technology to recreate, visualize and compute the human tumor microenvironment and its effects on cancer progression. We are building an atlas of cancer progression to help research hospitals/pharma test experimental drugs and to help clinicians evaluate potential treatment options for each patient to improve outcomes. Our technology...
Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he...
